Comparison of three assays for total and free PSA using hybritech and WHO calibrations

Manuel M. Garrido, Jose C. Marta, Ruy M. Ribeiro, Luis C. Pinheiro, Stefan Holdenrieder, Joao T. Guimaraes

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
3 Downloads (Pure)


Background/Aim: Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. Patients and Methods: A total of 233 men who underwent prostate biopsy (PSA: 2-10 ng/ml; Beckman Coulter Access® Hybritech® as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cobas® and the Abbott Architect® methods. Results: Roche tPSA values were ≈ 1% higher than Beckman, while Abbott values were ~5% lower. Roche had the highest diagnostic sensitivity (92%) compared to Beckman Coulter (87%) and Abbott (85%). Roche fPSA was ≈3% lower and Abbott ≈17% higher than that of Beckman. For the percentage of fPSA, Roche had the highest sensitivity (98%). Conclusion: Roche cobas® and Beckman Coulter Access® Hybritech® tPSA were almost interchangeable. While the agreement was acceptable for tPSA, this did not happen with fPSA and greater efforts for harmonization are required.

Original languageEnglish
Pages (from-to)3431-3439
Number of pages9
JournalIn Vivo
Issue number6
Publication statusPublished - Dec 2021


  • Free PSA
  • Hybritech calibration
  • Method comparison
  • Prostate cancer
  • Total PSA
  • WHO calibration


Dive into the research topics of 'Comparison of three assays for total and free PSA using hybritech and WHO calibrations'. Together they form a unique fingerprint.

Cite this